India RNA Therapeutics Market 2026 – 2035

The market in India is projected to reach around USD 50.5 million in 2025, USD 53.45 million in 2026 and USD 91.9 million in 2035 with a CAGR of 6.4% between 2026 and 2035. The main stimulus to market growth primarily comes in the form of the growing burden of chronic diseases, cancer, genetic disorders and infectious illnesses as well as the growth in demand for targeted and precision-based treatment methods in the hospitals, research centers, and pharmaceutical companies within India.

The further development of biotechnology infrastructure, the increased clinical trial activity, and the increased government and private investment in advanced therapeutic research also contribute to the development of the market. Moreover, making personalized medicine more popular, enhancing domestic production capacities of pharmaceuticals, and partnering with international biotech companies will most likely contribute to the long-term growth of the RNA therapeutics market in India during the forecast period.

Market Highlights

• By technology, mRNA therapeutics are expected to contribute over 40.5% of market revenue by 2025, driven by strong vaccine development and expanding biotech research.

• By application, infectious diseases are projected to grow at a CAGR of 6.6% from 2026 to 2035, supported by rising public health initiatives and rapid-response RNA treatments.

• Oncology and genetic disorders are anticipated to capture nearly 38.6% of total demand by 2030 as precision medicine adoption increases.

• Biotech and pharmaceutical companies will lead end-user adoption with around 47.5% market share in 2025, fueled by growing research pipelines and manufacturing capacity.

Significant Growth Factors

Blistering Technology Development of RNA Technology Platforms and Delivery Systems

The mRNA platform, RNA interference (RNAi), and gene-silencing technology are rapidly advancing to be more acculturated to the Indian RNA therapeutics market to seek higher therapeutic specificity and shorter drug development cycles. Over the past few years, the biotech companies and pharmaceutical firms in major centers of innovation have raised the number of research centers focusing on RNA, high-throughput screening centers, and scalable manufacturing platforms. The introduction of new improved systems of lipid nanoparticle delivery and improved systems of RNA stabilization has had an enormous impact on the effectiveness of treatment as well as the reduction of adverse effects. Clinical translation and shift to the next-generation RNA-based therapeutic approach may be conducted faster throughout the Indian healthcare system via such technological modernization.

These Areas of Improvement Help to Minim Disease Burden and Precision Medical Program Growth

The overall impact of the trend above is that there is a rapidly rising number of cases of cancer, chronic metabolic diseases, rare genetic diseases, and infectious diseases in India, which directly causes the increased demand for specifically targeted RNA therapeutics. There is increased clinical RNA-based treatment, national health activities in early diagnosis, vaccine development, and personal medicine. Both urban and semi-urban healthcare facilities are becoming more addicted to cancer and genetic screening programs, and the number of approved clinical trials and therapies is continuously rising. This growing healthcare interest in molecular-level interventions is leading to long-term investment into RNA drug pipelines and market expansion.

What Are the key Improvements of the Recasting the India RNA Therapeutics Market now?

Improvement of Regulatory Structures and Clinical Compliance Measures

The market of RNA therapeutics is being redefined in India because of the altering regulatory policy that has the ability to improve the safety, clinical transparency and quality control of advanced biologic and genetic therapies. Trying to comply with the international standards, the monitoring of drug clinical trials, post-market monitoring, and control of the manufacturers of the RNA-based drugs are becoming stricter and stricter among the health authorities of India. The present requirements to pharmaceutical companies and research centers are to possess a larger documenting record, patient safety track record, and data traceability during the development progress. As a result, many biotech firms have updated laboratory and quality control systems and compliance departments, accelerating the replacement of the antiquated research systems by the compliance standardized RNA development systems -leading to the gradual reinvestment in the sector.

Free RNA Delivery Technology, Automation, and Develop efficiency

To further increase the effectiveness of therapeutic treatment and reduce the negative outcomes, Indian biotech and pharmaceutical companies are quickly adopting new technology of RNA delivery that involves lipid nanoparticles, polymer carriers and targeted gene silencing technology. A lot of digital quality monitoring, automated manufacturing lines and high-throughput screening systems are contributing to the efficiency in production and reduction in development schedules. This is due to better formulation stability and scale-up production processes that are accelerating the process of laboratory discovery to human trials in clinical research centers. Such technological progress is rendering RNA therapies even more than the research tools that are still in their experimental stages become commercially viable and more precision-based solutions in the sphere of medicine.

Category Wise Insights

By Technology Type

Why is that the mRNA therapeutics are dominant in India?

The mRNA therapeutics dominate the Indian RNA market and are quick to make and have an outstanding history of vaccine performance in infectious disease and oncology with increasing applications. The already developed large-scale production capacity of biologics and the expanded biotech R&D in India have eased the process of clinical translation of mRNA platforms to become the most commercially advanced RNA technology in India.

Why is it the case that RNA Interference (RNAi) is cleaning up the floor?

RNAi therapies are also increasingly used in genetic diseases, liver diseases, and oncology because of their ability to silence genes on a specific basis. The RNAi pipeline is also an active area of study in Indian research centers, biotech start-up companies with high specificity and long-term consequences, and greater clinical validation worldwide.

Why would it be interesting in antisense oligonucleotide?

There is also the emergence of antisense treatments due to their success in rare genetics and also in neurological disorders. They are quite basic in their design and focus on action and thus are attractive to the customized medicine programs that are being introduced in the Indian research centers and hospitals.

Why does the gene-silencing therapies grow strategically essential?

There is also an adoption of the use of gene-silencing RNA technology in complicated chronic conditions where drugs do not work very well. It is their long-term economic opportunities of disease control and proper treatment that are stimulating investment, research, and relationships between pharmaceutical companies in India.

How is the future growth being impacted by the emerging RNA platforms?

The next-generation types of RNA are self-amplifying RNA and circular RNA which are becoming sources of first research financing due to stability, reduced dosing, and prolonged therapeutic impact - the growth drivers of the future.

By Therapeutic Application

So attractive in the market are infectious diseases?

Infectious diseases are the most widely used field since India has a significant focus on the innovation of vaccines, response to outbreaks, and the health of the population. The RNA-based vaccines and therapeutics are more readily developed and can be manufactured on a large scale, which is rather attractive to the national healthcare systems.

Why is oncology generally growing very fast?

The oncological trends, including rising cancer incidence and rising use of precision medicine, the need of RNA-based cancer vaccines, immune-modulating therapy, and gene-targeted treatment, are rising. The use of RNA in clinical trials is becoming more popular in hospitals and oncology centers in major cities.

Why is genetic diseases a high-growth market?

Efficiencies of the diagnostic tests and the heightened awareness of the rare conditions are contributing to the necessity of the usage of RNA therapeutics, which are based on the genetic etiology and not on the clinical presentation of the diseases. In specialized treatment centers, RNAi and antisense technology are gaining popularity in personalized methods of therapy.

What is catalyzing metabolic and cardiovascular illnesses?

The rising epidemic of diabetes, obesity, and heart disease in India is creating a high need for novel therapies that regulate gene expression and protein synthesis, in this scenario, RNA therapeutics have the potential to offer long term management of the disease.

So why are uncommon diseases receiving increasingly more investments?

In the case of RNA platforms, one can create targeted therapy for any disease that has no effective cure, and this is why biotech firms and research centers are keen to create orphan drugs with regulatory bonuses.

By End User

What is the secret of the domination of biotechnology-based organizations in the adoption of RNA therapeutics?

Biotech companies that are significant in the innovations of RNA platforms, delivery, and clinical pipelines dominate the market. The major sponsors of the startups and middle-size biotech firms are venture financing and strategic pharma alliances.

The question is what are the contributions of pharmaceutical companies to market expansion?

Big pharma is commercializing the RNA therapeutics with manufacturing capabilities, commercialization expertise, and distribution networks across the world, which are fast in approvals by regulatory bodies and market entry.

Why is there the increasing participation of hospitals?

The hospitals are new to the clinical trials, state-of-the-art treatment provision, and the personalized medicine programs. Oncology, genetic diseases, and treatment of infectious diseases are some of the areas in which healthcare institutions that are on the frontline are integrating RNA-based therapy in the treatment process.

How is the market being developed by the research institutions?

Academic centers and government research laboratories are the core of the Indian innovations in the field of RNA therapeutics, which result in early-stage discoveries, delivery innovation, and translational research.

Why then is the development of CDMOs in the RNA therapeutics rapid?

Governmental, international biotech companies are contracting out the particular manufacturing of RNA to the Contract Development and Manufacturing Organizations that are on the rise in size. Cost efficient production is making India a more popular outsourcing hub in the manufacture of RNA drugs since the country has acquired regulatory expertise and the ability to scale up to large volumes.

Report Scope

Top Players in the Market and Their Offerings

• Biocon Limited

• Pfizer Inc.

• Gennova Biopharmaceuticals Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Bharat Biotech International Ltd.

• Zydus Lifesciences Limited

• Cipla Limited

• Sun Pharmaceutical Industries Ltd.

• Serum Institute of India Pvt Ltd

• Novartis India Ltd.

• Others

Market News

India RNA therapeutics market is rapidly expanding with the top pharmaceutical and biotechnology firms developing leading RNA technologies, the development of local R&D and manufacturing facilities, and the clinical and commercial adoption of RNA based therapies.

• Cipla Limited: In June 2024, Cipla announced it will incur significant expenditures on mRNA technology with its partner Ethris in an attempt to develop RNA-based therapeutics in India to help treat infectious and rare diseases.

• The company manufactures generic drugs, each of which is also invented by this company. Later on in March 2025, the acquisition of Checkpoint Therapeutics by Sun Pharma can be added to its retinue of RNA-based oncology and immunotherapy.

• Novartis India Ltd.: To accelerate the clinical trials and commercialization, in December 2025, Novartis increased its Indian-based research and development facility with a complex RNA platform and silencing gene research facilities.

These include the improvement of production locally and awareness creation on treatment and utilizing RNA therapeutics in hospitals, research centers, and biotechnological institutes in India.

The India RNA Therapeutics Market is segmented as follows:

By Technology Type

• mRNA Therapeutics

• RNA Interference (RNAi)

• Antisense Oligonucleotides

• Gene-Silencing Therapies

• Emerging RNA Platforms

• Others

By Therapeutic Application

• Infectious Diseases

• Oncology (Cancer)

• Genetic Disorders

• Metabolic Diseases

• Cardiovascular Diseases

• Rare Diseases

• Others

By End User

• Hospitals

• Specialty Clinics

• Biotechnology Companies

• Pharmaceutical Companies

• Research Institutions

• Contract Manufacturing Organizations (CDMOs)

• Others